{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:19:21Z","timestamp":1778703561655,"version":"3.51.4"},"reference-count":228,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19\u2019s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1232472","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:03:13Z","timestamp":1694437393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale for combined therapies in severe-to-critical COVID-19 patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Aitor","family":"Gonzaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etelvina","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis M.","family":"Hern\u00e1ndez-Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rut","family":"Meseguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Al-Akioui-Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Soria-Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Carlos","family":"Sanjuan-Gimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ferreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"Tejedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Lopez-Lluch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Goterris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Maci\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Sempere-Ortells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelkrim","family":"Hmadcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristobal","family":"Aguilar-Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Arbona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Tar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco M.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Jaime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Ferreres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Figueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Ca\u00f1ada-Illana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Querol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Eguizabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mart\u00edn-Quir\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Robles-Marhuenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"key":"B1","volume-title":"International Health Regulations Emergency Committee on Novel Coronavirus in China","author":"Organization","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01244-13","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group","volume":"87","author":"de Groot","year":"2013","journal-title":"J Virol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd9149","article-title":"Airborne transmission of respiratory viruses","volume":"373","author":"Wang","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2009249","article-title":"Mild or moderate Covid-19","volume":"383","author":"Gandhi","year":"2020","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0504","article-title":"The InCubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application","volume":"172","author":"Lauer","year":"2020","journal-title":"Ann Internal Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Internal Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention","volume":"323","author":"Wu","year":"2020","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline characteristics and outcomes of 1591 patients infected with SARS-coV-2 admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"G\u00f6tzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"B13","volume-title":"World Health Organization and R&D Blueprint strategy for COVID-19","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0130","article-title":"Are older people really more susceptible to SARS-coV-2","volume":"13","author":"Zhang","year":"2022","journal-title":"Aging Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London England)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-055765","article-title":"Severity of acute COVID-19 in children <18 years old march 2020 to december 2021","volume":"149","author":"Forrest","year":"2022","journal-title":"Pediatrics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6924e2","article-title":"Coronavirus disease 2019 case surveillance - United States, january 22-may 30, 2020","volume":"69","author":"Stokes","year":"2020","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7326\/M20-6976","article-title":"The proportion of SARS-coV-2 infections that are asymptomatic: A systematic review","volume":"174","author":"Oran","year":"2021","journal-title":"Ann Internal Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13554","DOI":"10.1111\/eci.13554","article-title":"Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations","volume":"51","author":"Ioannidis","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.09.1464","article-title":"A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates","volume":"101","author":"Meyerowitz-Katz","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B21","year":"2022"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","article-title":"The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies","volume":"551","author":"Seyed Hosseini","year":"2020","journal-title":"Virology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet (London England)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2294","article-title":"SARS-coV-2 variants of concern in the United States-challenges and opportunities","volume":"325","author":"Walensky","year":"2021","journal-title":"Jama"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.10.020","article-title":"SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis","volume":"27","author":"Rostami","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30631-9","article-title":"SeroTracker: a global SARS-CoV-2 seroprevalence dashboard","volume":"21","author":"Arora","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijid.2021.12.353","article-title":"Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis","volume":"116","author":"Jahan","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101053","DOI":"10.1016\/j.eclinm.2021.101053","article-title":"Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic","volume":"39","author":"Hotez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02835-X","article-title":"COVID-19 vaccine strategies must focus on severe disease and global equity","volume":"399","author":"McIntyre","year":"2022","journal-title":"Lancet (London England)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"Leung","year":"2021","journal-title":"Eur Communicable Dis Bull"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20371","DOI":"10.1039\/d2cp00469k","article-title":"Computational investigation of the increased virulence and pathogenesis of SARS-CoV-2 lineage B.1.1.7","volume":"24","author":"Murugan","year":"2022","journal-title":"Phys Chem Chem Phys"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1362445\/v1","article-title":"Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant","author":"Chen","year":"2022","journal-title":"ArXiv"},{"key":"B34","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines","volume-title":"National Institutes of Health","year":""},{"key":"B35","doi-asserted-by":"publisher","first-page":"n3144","DOI":"10.1136\/bmj.n3144","article-title":"Covid-19: Early studies give hope omicron is milder than other variants","volume":"375","author":"Christie","year":"2021","journal-title":"BMJ (Clin Res ed)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24315","article-title":"Winter of omicron-the evolving COVID-19 pandemic","volume":"327","author":"Del Rio","year":"2022","journal-title":"Jama"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00019-0","article-title":"Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study","volume":"21","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"m3339","DOI":"10.1136\/bmj.m3339","article-title":"Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score","volume":"370","author":"Knight","year":"2020","journal-title":"BMJ (Clin Res ed)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-0716-0211-9_3","article-title":"Biochemical characterization of Middle East respiratory syndrome coronavirus spike protein proteolytic processing","volume":"2099","author":"Whittaker","year":"2020","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"118219","DOI":"10.1016\/j.lfs.2020.118219","article-title":"Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2","volume":"259","author":"Mohammad","year":"2020","journal-title":"Life Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.033","article-title":"Higher binding affinity of furin for SARS-CoV-2 spike (S) protein D614G mutant could be associated with higher SARS-CoV-2 infectivity","volume":"103","author":"Mohammad","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9050331","article-title":"The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms","volume":"9","author":"Alanagreh","year":"2020","journal-title":"Pathog (Basel Switzerland)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri2436","article-title":"Viral evasion and subversion of pattern-recognition receptor signalling","volume":"8","author":"Bowie","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7092","DOI":"10.1038\/s41467-021-27318-0","article-title":"Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2","volume":"12","author":"Hatton","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"M\u00fcller","year":"1994","journal-title":"Sci (New York NY)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e0249090","DOI":"10.1371\/journal.pone.0249090","article-title":"Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis","volume":"16","author":"Alene","year":"2021","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e049752","DOI":"10.1136\/bmjopen-2021-049752","article-title":"Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies","volume":"11","author":"Chen","year":"2021","journal-title":"BMJ Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.591372","article-title":"Estimating the prevalence of asymptomatic COVID-19 cases and their contribution in transmission - using henan province, China, as an example","volume":"8","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2137257","DOI":"10.1001\/jamanetworkopen.2021.37257","article-title":"Global percentage of asymptomatic SARS-coV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Network Open"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10071049","article-title":"Percentage of asymptomatic infections among SARS-coV-2 omicron variant-positive individuals: A systematic review and meta-analysis","volume":"10","author":"Shang","year":"2022","journal-title":"Vaccines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2019716118","article-title":"Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity","volume":"118","author":"Subramanian","year":"2021","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B57","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s13287-020-01964-5","article-title":"Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing","volume":"11","author":"Eguizabal","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.620730","article-title":"SARS-coV-2-specific memory T lymphocytes from COVID-19 convalescent donors: identification, biobanking, and large-scale production for adoptive cell therapy","volume":"9","author":"Ferreras","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: Neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J Exp Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00641","article-title":"Neutrophils, crucial, or harmful immune cells involved in coronavirus infection: A bioinformatics study","volume":"11","author":"Hemmat","year":"2020","journal-title":"Front Genet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200678","article-title":"The many faces of the anti-COVID immune response","volume":"217","author":"Vardhana","year":"2020","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01169","article-title":"Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention","volume":"11","author":"Hussman","year":"2020","journal-title":"Front Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"945576","DOI":"10.1101\/2020.02.12.945576","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","author":"Haiming","year":"2020","journal-title":"bioRxiv"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J Med Virol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"153848","DOI":"10.1016\/j.prp.2022.153848","article-title":"The role of antigen-presenting cells in the pathogenesis of COVID-19","volume":"233","author":"Farzi","year":"2022","journal-title":"Pathol Res Practice"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.009","article-title":"The innate immune system: fighting on the front lines or fanning the flames of COVID-19","volume":"27","author":"McKechnie","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"New Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/path.2067","article-title":"Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS","volume":"210","author":"He","year":"2006","journal-title":"J Pathol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J Gen Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer","volume":"15","author":"Tian","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200606027","article-title":"Novel cell death program leads to neutrophil extracellular traps","volume":"176","author":"Fuchs","year":"2007","journal-title":"J Cell Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1083\/jcb.200606027","article-title":"Neutrophil extracellular traps go viral","volume":"7","author":"Sch\u00f6nrich","year":"2016","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1160\/TH17-09-0630","article-title":"The pathophysiological role of neutrophil extracellular traps in inflammatory diseases","volume":"118","author":"Bonaventura","year":"2018","journal-title":"Thromb Haemostasis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0148142","DOI":"10.1371\/journal.pone.0148142","article-title":"Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis","volume":"11","author":"Czaikoski","year":"2016","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/ITT.S280706","article-title":"Cellular and humoral immune responses in covid-19 and immunotherapeutic approaches","volume":"10","author":"Hasan","year":"2021","journal-title":"ImmunoTargets Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2010.01427.x","article-title":"Development of a dose-response model for SARS coronavirus","volume":"30","author":"Watanabe","year":"2010","journal-title":"Risk Anal"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63537.sa2","article-title":"Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events","volume":"10","author":"Goyal","year":"2021","journal-title":"eLife"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.3346\/jkms.2020.35.e86","article-title":"Viral load kinetics of SARS-coV-2 infection in first two patients in Korea","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet (London England)"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-022-01043-6","article-title":"Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12892","article-title":"Cross talk between intracellular pathogens and cell death","volume":"297","author":"Demarco","year":"2020","journal-title":"Immunol Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2019.12.008","article-title":"The involvement of regulated cell death forms in modulating the bacterial and viral pathogenesis","volume":"353","author":"Imre","year":"2020","journal-title":"Int Rev Cell Mol Biol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/22221751.2021.1872353","article-title":"The interplay between emerging human coronavirus infections and autophagy","volume":"10","author":"Zhao","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B92","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-020-00334-0","article-title":"SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26742","article-title":"Apoptosis-induced T-cell lymphopenia is related to COVID-19 severity","volume":"93","author":"Cizmecioglu","year":"2021","journal-title":"J Med Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","article-title":"The \u2018cytokine storm\u2019: molecular mechanisms and therapeutic prospects","volume":"42","author":"Karki","year":"2021","journal-title":"Trends Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 Triggers inflammatory cell death, tissue damage, and mortality in SARS-coV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severities: A multicenter study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.17240","article-title":"COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies","volume":"193","author":"Calabretta","year":"2021","journal-title":"Br J Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet (London England)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00652-2021","article-title":"Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit","volume":"8","author":"Yuan","year":"2022","journal-title":"ERJ Open Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202007-2676LE","article-title":"Injury to the endothelial glycocalyx in critically ill patients with COVID-19","volume":"202","author":"Stahl","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199502233320802","article-title":"The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion","volume":"332","author":"Anderson","year":"1995","journal-title":"New Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet (London England)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.734384","article-title":"Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis","volume":"117","author":"Flammer","year":"2008","journal-title":"Circulation"},{"key":"B106","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","article-title":"COVID-19: immunopathogenesis and immunotherapeutics","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/all.14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","volume":"75","author":"Zhang","year":"2020","journal-title":"Allergy"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00090-07","article-title":"Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein","volume":"81","author":"Tan","year":"2007","journal-title":"J Virol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27489","article-title":"Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis","volume":"94","author":"Moosazadeh","year":"2022","journal-title":"J Med Virol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.eclinm.2020.100454","article-title":"Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation","volume":"25","author":"S\u00e1nchez-Guijo","year":"2020","journal-title":"A Proof Concept Study EClinMed"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01979","article-title":"Innate immune responses to highly pathogenic coronaviruses and other significant respiratory viral infections","volume":"11","author":"Ahmed-Hassan","year":"2020","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e12666","DOI":"10.1002\/rth2.12666","article-title":"COVID-19 and venous thromboembolism: A narrative review","volume":"6","author":"Angelini","year":"2022","journal-title":"Res Pract Thromb Haemostasis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e200308","DOI":"10.1148\/ryct.2020200308","article-title":"Pulmonary embolism at CT pulmonary angiography in patients with COVID-19","volume":"2","author":"Kaminetzky","year":"2020","journal-title":"Radiol Cardiothoracic Imag"},{"key":"B116","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1148\/radiol.2020203557","article-title":"Pulmonary embolism and deep vein thrombosis in COVID-19: A systematic review and meta-analysis","volume":"298","author":"Suh","year":"2021","journal-title":"Radiology"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31305-2","article-title":"Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series","volume":"396","author":"Bradley","year":"2020","journal-title":"Lancet (London England)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"118482","DOI":"10.1016\/j.lfs.2020.118482","article-title":"Cardiac inflammation in COVID-19: Lessons from heart failure","volume":"260","author":"Unudurthi","year":"2020","journal-title":"Life Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Internal Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"112158","DOI":"10.1016\/j.biopha.2021.112158","article-title":"A mini-review on the impact of COVID 19 on vital organs","volume":"143","author":"Shah","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.988536","article-title":"The role of B cells in COVID-19 infection and vaccination","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12964-022-00967-4","article-title":"Correction: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)","volume":"20","author":"Mohammed","year":"2022","journal-title":"Cell Communication Signaling"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00436-4","article-title":"Not just antibodies: B cells and T cells mediate immunity to COVID-19","volume":"20","author":"Cox","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2139\/ssrn.3720301","article-title":"Alterations in T and B cell function persist in convalescent COVID-19 patients","volume":"2","author":"Shuwa","year":"2021","journal-title":"Med (New York NY)"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet (London England)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400593111","article-title":"Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection","volume":"111","author":"Teijaro","year":"2014","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0331-4","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","volume":"20","author":"Merad","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0377","article-title":"The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study","volume":"58","author":"Zheng","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2011.04327.x","article-title":"Immunomodulatory properties and therapeutic application of mesenchymal stem cells","volume":"164","author":"Shi","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14849","article-title":"Thromboinflammation and the hypercoagulability of COVID-19","volume":"18","author":"Connors","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"104380","DOI":"10.1016\/j.jcv.2020.104380","article-title":"Supportive treatment with tocilizumab for COVID-19: A systematic review","volume":"127","author":"Alzghari","year":"2020","journal-title":"J Clin Virol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","volume":"323","author":"Sanders","year":"2020","journal-title":"Jama"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: What\u2019s next","volume":"177","author":"Scavone","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"Jama"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152740","article-title":"A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia","volume":"131","author":"Avenda\u00f1o-Sol\u00e1","year":"2021","journal-title":"J Clin Invest"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02172-x","article-title":"Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19","volume":"50","author":"Bautista-Vargas","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"101508","DOI":"10.1016\/j.smim.2021.101508","article-title":"Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion","volume":"55","author":"Mazzoni","year":"2021","journal-title":"Semin Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrobial Agents"},{"key":"B145","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review","volume":"27","author":"Cortegiani","year":"2021","journal-title":"Pulmonology"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690477","article-title":"The many faces of JAKs and STATs within the COVID-19 storm","volume":"12","author":"Grant","year":"2021","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092324","article-title":"The JAK1\/2 inhibitor baricitinib mitigates the spike-induced inflammatory response of immune and endothelial cells in vitro","volume":"10","author":"Barilli","year":"2022","journal-title":"Biomedicines"},{"key":"B152","year":"2022"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01266-w","article-title":"COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency","volume":"43","author":"Isidori","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.23812\/20-EDITORIAL_1-5","article-title":"Dexamethasone for COVID-19? Not so fast","volume":"34","author":"Theoharides","year":"2020","journal-title":"J Biol Regulators Homeostatic Agents"},{"key":"B155","doi-asserted-by":"publisher","first-page":"108121","DOI":"10.1016\/j.intimp.2021.108121","article-title":"Effectiveness of corticosteroids to treat severe COVID-19: A systematic review and meta-analysis of prospective studies","volume":"100","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"20587384211063976","DOI":"10.1177\/20587384211063976","article-title":"Systemic corticosteroids for management of COVID-19: Saving lives or causing harm","volume":"35","author":"FakhriRavari","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1002\/acg2.101","article-title":"Rapid production of clinical-grade SARS-CoV-2 specific T cells","volume":"3","author":"Leung","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.063","article-title":"Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection","volume":"34","author":"Ng","year":"2016","journal-title":"Vaccine"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.114","article-title":"Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis","volume":"49","author":"Teschner","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.324","article-title":"Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic Malignancies","volume":"50","author":"Triplett","year":"2015","journal-title":"Bone Marrow Transplantation"},{"key":"B162","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.eclinm.2021.101086","article-title":"Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)","volume":"39","author":"P\u00e9rez-Mart\u00ednez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1083215","article-title":"CD45RA- T cells to treat severe refractory infections in immunocompromised patients","volume":"10","author":"Al-Akioui Sanz","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01151","article-title":"Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus","volume":"10","author":"Soria-Juan","year":"2019","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080886","article-title":"Mesenchymal stem cells for regenerative medicine","volume":"8","author":"Han","year":"2019","journal-title":"Cells"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Sci (New York NY)"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5309.71","article-title":"Marrow stromal cells as stem cells for nonhematopoietic tissues","volume":"276","author":"Prockop","year":"1997","journal-title":"Sci (New York NY)"},{"key":"B168","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-020-02380-2","article-title":"Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients","volume":"18","author":"Rogers","year":"2020","journal-title":"J Trans Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00224-0","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis","volume":"3","author":"Hashmi","year":"2016","journal-title":"Lancet Haematol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet (London England)"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932360","article-title":"Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: preliminary results of a phase I\/II clinical trial","volume":"13","author":"Gr\u00e9goire","year":"2022","journal-title":"Front Immunol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.56","article-title":"Immunomodulatory therapy for severe influenza","volume":"9","author":"Darwish","year":"2011","journal-title":"Expert Rev Anti-infective Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e21429","DOI":"10.1097\/MD.0000000000021429","article-title":"Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine"},{"key":"B174","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","article-title":"Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"6","author":"Shi","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.21-0046","article-title":"Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial","volume":"10","author":"Dilogo","year":"2021","journal-title":"Stem Cells Trans Med"},{"key":"B177","doi-asserted-by":"publisher","first-page":"e48052","DOI":"10.15252\/embr.201948052","article-title":"Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response","volume":"21","author":"Court","year":"2020","journal-title":"EMBO Rep"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2736","article-title":"Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury","volume":"18","author":"Islam","year":"2012","journal-title":"Nat Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.034","article-title":"Long-term follow-up of a pilot study using placenta-derived decidua stromal cells for severe acute graft-versus-host disease","volume":"25","author":"Sadeghi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03125-1","article-title":"Biological functions of mesenchymal stem cells and clinical implications","volume":"76","author":"Naji","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02056","article-title":"The use of human mesenchymal stem cells as therapeutic agents for the in vivo treatment of immune-related diseases: A systematic review","volume":"9","author":"Leyendecker","year":"2018","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8071025","article-title":"The immunomodulatory functions of mesenchymal stromal\/stem cells mediated via paracrine activity","volume":"8","author":"Zhou","year":"2019","journal-title":"J Clin Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2020.06.018","article-title":"Expanded mesenchymal stem cells: a novel therapeutic approach for SARS-CoV-2 pneumonia (COVID-19). Concepts regarding a first case in Spain","volume":"155","author":"Soler Rich","year":"2020","journal-title":"Med Clin (English ed)"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00858-2020","article-title":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19","volume":"55","author":"Khoury","year":"2020","journal-title":"Eur Respir J"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0186","article-title":"Current status of mesenchymal stem cell therapy for immune\/inflammatory lung disorders: Gleaning insights for possible use in COVID-19","volume":"9","author":"Yen","year":"2020","journal-title":"Stem Cells Trans Med"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: time to change the name","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Trans Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.07.023","article-title":"Mesenchymal stem\/stromal cell extracellular vesicles: From active principle to next generation drug delivery system","volume":"262","author":"Crivelli","year":"2017","journal-title":"J Controlled Release"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0146","article-title":"Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome","volume":"9","author":"Qu","year":"2020","journal-title":"Stem Cells Trans Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.997204","article-title":"Homing properties of mesenchymal stromal cells","volume":"15","author":"Kallmeyer","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B190","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/stcltm\/szac032","article-title":"Efficacy and safety of MSC cell therapies for hospitalized patients with COVID-19: A systematic review and meta-analysis","volume":"11","author":"Qu","year":"2022","journal-title":"Stem Cells Trans Med"},{"key":"B191","first-page":"79","article-title":"Mesenchymal stem cell therapy for COVID-19","volume":"10","author":"Sengul","year":"2021","journal-title":"Am J Stem Cells"},{"key":"B192","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41536-021-00181-9","article-title":"Stem cell-based therapy for COVID-19 and ARDS: a systematic review","volume":"6","author":"Zanirati","year":"2021","journal-title":"NPJ Regenerative Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.1218","article-title":"Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress syndrome due to COVID 19","volume":"12","author":"Iglesias","year":"2021","journal-title":"Aging Dis"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0810-9","article-title":"Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19","volume":"14","author":"Tang","year":"2020","journal-title":"Front Med"},{"key":"B195","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.ebiom.2022.103920","article-title":"Mesenchymal stem cell treatment for COVID-19","volume":"77","author":"Xu","year":"2022","journal-title":"EBioMedicine"},{"key":"B196","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13287-021-02165-4","article-title":"Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series","volume":"12","author":"Hashemian","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1002\/ctm2.297","article-title":"Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial","volume":"11","author":"Xu","year":"2021","journal-title":"Clin Trans Med"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16986","article-title":"Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells","volume":"25","author":"Sadeghi","year":"2021","journal-title":"J Cell Mol Med"},{"key":"B199","doi-asserted-by":"publisher","first-page":"895714","DOI":"10.1155\/2015\/895714","article-title":"Bottlenecks in the efficient use of advanced therapy medicinal products based on mesenchymal stromal cells","volume":"2015","author":"Escacena","year":"2015","journal-title":"Stem Cells Int"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2003.07.005","article-title":"Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells","volume":"33","author":"Stenderup","year":"2003","journal-title":"Bone"},{"key":"B201","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","article-title":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial","volume":"5","author":"Meng","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B202","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s13287-021-02483-7","article-title":"Cell therapy in patients with COVID-19 using Wharton\u2019s jelly mesenchymal stem cells: a phase 1 clinical trial","volume":"12","author":"Saleh","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1177\/0885066621997365","article-title":"Mesenchymal stem cell therapy for severe COVID-19 ARDS","volume":"36","author":"H\u00e4berle","year":"2021","journal-title":"J Intensive Care Med"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1\/2a, randomized controlled trial","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Trans Med"},{"key":"B205","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1574888X13666180913123424","article-title":"The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review","volume":"14","author":"Golchin","year":"2019","journal-title":"Curr Stem Cell Res Ther"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-020-03475-w","article-title":"Vaccine against covid-19 disease - present status of development","volume":"87","author":"Dutta","year":"2020","journal-title":"Indian J Pediatrics"},{"key":"B207","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","article-title":"Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis","volume":"11","author":"Rotshild","year":"2021","journal-title":"Sci Rep"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, immunogenicity and safety of COVID-19 vaccines: A systematic review and meta-analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front Immunol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2110300","article-title":"Efficacy of natural immunity against SARS-coV-2 reinfection with the beta variant","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"New Engl J Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet (London England)"},{"key":"B211","doi-asserted-by":"publisher","first-page":"e13520","DOI":"10.1111\/eci.13520","article-title":"SARS-CoV-2 re-infection risk in Austria","volume":"51","author":"Pilz","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B212","doi-asserted-by":"publisher","first-page":"108814","DOI":"10.1016\/j.clim.2021.108814","article-title":"Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection","volume":"230","author":"Dehgani-Mobaraki","year":"2021","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.770381","article-title":"Long-lasting immunity against SARS-coV-2: dream or reality","volume":"8","author":"Gussarow","year":"2021","journal-title":"Front Med"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.793953","article-title":"Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 months after SARS-coV-2 infection","volume":"12","author":"Rosati","year":"2021","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab999","article-title":"Duration of severe acute respiratory syndrome coronavirus 2 natural immunity and protection against the delta variant: A retrospective cohort study","volume":"75","author":"Kim","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab234","article-title":"Reinfection rates among patients who previously tested positive for coronavirus disease 2019: A retrospective cohort study","volume":"73","author":"Sheehan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B217","doi-asserted-by":"publisher","first-page":"112911","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7044e1","article-title":"Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-coV-2 immunity - nine states, january-september 2021","volume":"70","author":"Bozio","year":"2021","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab608","article-title":"An observational cohort study on the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status","volume":"74","author":"Lumley","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac022","article-title":"Necessity of coronavirus disease 2019 (COVID-19) vaccination in persons who have already had COVID-19","volume":"75","author":"Shrestha","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B221","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12979-016-0071-2","article-title":"Nutrigerontology: a key for achieving successful ageing and longevity","volume":"13","author":"Aiello","year":"2016","journal-title":"Immun Ageing"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7032e1","article-title":"Reduced risk of reinfection with SARS-coV-2 after COVID-19 vaccination - kentucky, may-june 2021","volume":"70","author":"Cavanaugh","year":"2021","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19623","article-title":"Association of prior SARS-coV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar","volume":"326","author":"Abu-Raddad","year":"2021","journal-title":"Jama"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.02.006","article-title":"Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: A hint for COVID-19 treatment","volume":"6","author":"Chen","year":"2020","journal-title":"Eng (Beijing China)"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1644","article-title":"Severe acute lung injury related to COVID-19 infection: A review and the possible role for escin","volume":"60","author":"Gallelli","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s13287-021-02502-7","article-title":"Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19","volume":"12","author":"da Silva","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070993","article-title":"COVID-19: unmasking emerging SARS-coV-2 variants, vaccines and therapeutic strategies","volume":"11","author":"Raman","year":"2021","journal-title":"Biomolecules"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00088-1","article-title":"Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial","volume":"10","author":"Wolfe","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1232472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T13:03:20Z","timestamp":1694437400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1232472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":228,"alternative-id":["10.3389\/fimmu.2023.1232472"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1232472","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"article-number":"1232472"}}